Curis, Inc. · NASDAQ:CRIS

Curis — Investor Presentation (June 2022)

50 slides from Curis's investor presentation, Jun 1, 2022

  1. Slide 1: Corporate Presentation

    Corporate Presentation NASDAQ: CRIS

  2. Slide 2: Cautionary Note Regarding Forward Looking Statements

    Cautionary Note Regarding Forward Looking Statements This presentation contains certain forward-looking statements about Curis, Inc. (“we,” “us,” or the “Company”) within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Words such as “expect(s),” “believe(s),” “will,”

  3. Slide 3: Corporate Overview

    Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $120.7M as of March 31, 2022; cash runway into 2024 Emavusertib: first-in-cla

  4. Slide 4: Pipeline

    Pipeline Curis develops novel, first-in-class cancer drugs PRE-CLINICAL CLINICAL MARKETED Indication Proof of Principle Safety Dose Optimization Clinical Activity Pivotal Commercial Two programs Heme Malignancies are the focus of this presentation Emavusertib* IRAK4-driven Leukemia IRAK4 (AML/MDS) T

  5. Slide 5: IRAK4 Biology and emavusertib (CA-4948)

    IRAK4 Biology and emavusertib (CA-4948)

  6. Slide 6: IRAK4 Biology and Emavusertib

    IRAK4 Biology and Emavusertib IRAK4 is a novel and important target across multiple heme malignancies IRAK4 in AML/MDS IRAK4 in B Cell Cancers Spliceosome mutation drives overexpression of IRAK4-L TLR Pathway is dependent upon IRAK4 for function (which causes constitutive activation of the myddosome

  7. Slide 7: Emavusertib is the Leading IRAK4 Inhibitor in Development for Cancer

    Emavusertib is the Leading IRAK4 Inhibitor in Development for Cancer Targeted design offers added potential benefit of also hitting FLT3 In Nov 2020, the NCI selected emavusertib, Curis’s first-in-class IRAK4 inhibitor, and entered into an agreement Emavusertib Emavusertib (“CRADA”) with Curis to co

  8. Slide 8: Emavusertib PK/PD

    Emavusertib PK/PD Attractive PK profile supports BID dosing and high target suppression Attractive PK Profile High Target Suppression • Half-life of ~6 hours Trough • Exposure at RP2D correlates with 98% inhibition Exposure Dose Inhibition • Supports BID dosing regimen 2.5μM 200mg 97% 4.1μM 300mg 98

  9. Slide 9: Emavusertib (CA-4948) Preclinical Data

    Emavusertib (CA-4948) Preclinical Data Clear anti-cancer activity suggests broad potential across heme malignancies AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Therapy Combination Therapy Monotherapy vs. Combination p<0.05 100 in OCI-Ly10 model2 vehicle Vehicle 1200 Relative Cell Growth %

  10. Slide 10: Emavusertib Clinical Plan

    Emavusertib Clinical Plan Ongoing clinical studies in AML/MDS and B cell cancers AML/MDS AML/MDS B Cell Cancers Monotherapy Combination Therapy Combination Therapy (relapsed/refractory) (relapsed/refractory) (relapsed/refractory) Patients Patients Patients with IRAK4 Pathway activation with Targeted

  11. Slide 11: Emavusertib in AML/MDS

    Emavusertib in AML/MDS

  12. Slide 12: Emavusertib in AML/MDS

    Emavusertib in AML/MDS Clinical studies designed to leverage the role of IRAK4/FLT3 in AML/MDS % of Patient Disease Driver Population IRAK4-L > 50%1 Rationale for Monotherapy FLT3 25-30%2 • IRAK4 / FLT3 is the largest targeted market in AML/MDS1,2 TET2 10-20%3 • Spliceosome mutation is a leading cau

  13. Slide 13: Emavusertib in AML and MDS

    Emavusertib in AML and MDS TakeAim Leukemia Trial - Open-label, single arm, Phase 1/2 dose escalation and expansion study Dose Escalation: Dose Expansion: 200/300/400/500 mg BID 300 mg BID Study Objectives 1ᵒ: Determine maximum tolerated dose Determine recommended Phase 2 dose 2ᵒ: Pharmacokinetic (P

  14. Slide 14: Safety Profile for emavusertib

    Safety Profile for emavusertib 49 total patients with AML/MDS treated with emavusertib Recommended Phase 2 Dose 200 mg BID 300 mg BID 400 mg BID 500 mg BID Grade 3+ Treatment-Related Adverse Event (N = 3) (N = 26) (N = 17) (N = 3) n (%) n (%) n (%) n (%) Number of patients having grade 3+ treatment-

  15. Slide 15: Encouraging Clinical Activity in R/R AML/MDS Patient Populations

    Encouraging Clinical Activity in R/R AML/MDS Patient Populations Emavusertib shows activity as a monotherapy in patients with Spliceosome and FLT3 mutations Best Response Efficacy Population #1: AML Spliceosome Patients1 CR/CRh Rate 2/5 (40%) The CR and CRh patients CR 1/5 (20%) are both MRD-negativ

  16. Slide 16: Clinical Data: R/R AML Patients with Spliceosome Mutation

    Clinical Data: R/R AML Patients with Spliceosome Mutation Patient Population #1 16

  17. Slide 17: Unmet Need for R/R AML Patients with Spliceosome Mutation

    Unmet Need for R/R AML Patients with Spliceosome Mutation No approved targeted therapies and no unified standard of care for these patients Elderly / • Spliceosome mutations occur in ~10% of AML patients1 Intensive Non-Intensive Induction Ven/HMA - These mutations create a chronic inflammatory marro

  18. Slide 18: Initial Emavusertib Data Compare Favorably to Existing Therapies

    Initial Emavusertib Data Compare Favorably to Existing Therapies Potential to meaningfully improve outcomes in R/R AML patients with spliceosome mutation Most Commonly Used Therapies in R/R AML Patients without FLT3 Mutation1 Emavusertib Decitabine2,3 Azacitidine2,4 LoDAC5 patients achieving CR/CRh

  19. Slide 19: Encouraging Clinical Activity in R/R AML Patients with Spliceosome Mutation

    Encouraging Clinical Activity in R/R AML Patients with Spliceosome Mutation Achieved 40% CR/CRh rate, with treatment duration >6 months to date in responding patients Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx Risk Category emavusertib % Change (BID) Mutations Baseline

  20. Slide 20: Clinical Data: R/R MDS Patients with Spliceosome Mutation

    Clinical Data: R/R MDS Patients with Spliceosome Mutation Patient Population #2 20

  21. Slide 21: Spliceosome Mutations Common in MDS

    Spliceosome Mutations Common in MDS Large unmet need for R/R MDS patients with spliceosome mutation • Spliceosome mutations (U2AF1/SF3B1) are the most prominent mutations in MDS, accounting for ~30% of all MDS patients1 SCT Eligible Not SCT Eligible HMA HMA - These mutations create a chronic inflamm

  22. Slide 22: Clear Unmet Need in Relapsed/Refractory MDS

    Clear Unmet Need in Relapsed/Refractory MDS Current standard of care offers little therapeutic benefit to patients Most Commonly Used Therapies in R/R MDS1 Emavusertib Chemotherapy2 Decitabine3 Azacitidine3 IRAK4 Inhibitor Chemotherapy HMA HMA • 57% mCR rate • ~8% ORR • 2nd line response data • 2nd

  23. Slide 23: Encouraging Clinical Activity in R/R MDS Patients with Spliceosome Mutation

    Encouraging Clinical Activity in R/R MDS Patients with Spliceosome Mutation Marrow blast reduction achieved in 5 of 7 patients, including 4 marrow CRs Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx IPSS-R emavusertib % Change (BID) Mutations # Baseline Response Therapy (mo

  24. Slide 24: Clinical Data: R/R AML Patients with FLT3 Mutation

    Clinical Data: R/R AML Patients with FLT3 Mutation Patient Population #3 24

  25. Slide 25: IRAK4 Signaling Drives Resistance to FLT3 Inhibitors

    IRAK4 Signaling Drives Resistance to FLT3 Inhibitors IRAK4 inhibition is synergistic with, and prevents adaptive resistance to, FLT3 inhibition IRAK Activity IRAK1/4i Synergy with FLT3i Leukemia-free Survival increases after treatment with FLT3i IRAK1/4i + FLT3i Combination vs FLT3i alone 100 – 100

  26. Slide 26: Emavusertib May Address Unmet Need in R/R AML Patients with FLT3 Mut

    Emavusertib May Address Unmet Need in R/R AML Patients with FLT3 Mut No approved therapies for patients R/R to FLT3 inhibitors Most Commonly Used Therapies in R/R AML Patients with FLT3 Mutation1 Emavusertib Gilteritinib2,3 Azacitidine2 Decitabine2 IRAK4 Inhibitor FLT3 Inhibitor HMA HMA • 33% CR • ~

  27. Slide 27: Encouraging Clinical Activity in R/R AML Patients with FLT3 Mutation

    Encouraging Clinical Activity in R/R AML Patients with FLT3 Mutation Achieving disease modification in heavily pretreated patients with emavusertib monotherapy Risk Prior Therapies Duration on Dose Baseline Molecular Blasts Blasts Best Dx Category emavusertib % Change (BID) Mutations Baseline Respon

  28. Slide 28: Emavusertib Has Potential to Address Clear Unmet Need in AML and MDS

    Emavusertib Has Potential to Address Clear Unmet Need in AML and MDS First-in-class IRAK4 inhibitor targets specific genetic populations in AML and MDS Emavusertib addresses a novel target (IRAK4) and: (1) demonstrates clear anti-cancer activity as an oral single agent (2) is active in genetically-d

  29. Slide 29: Emavusertib in B Cell Cancers

    Emavusertib in B Cell Cancers

  30. Slide 30: Emavusertib in B Cell Cancers

    Emavusertib in B Cell Cancers Combination therapy provides complimentary inhibition of two pathways that drive NF-κB Two Pathways Drive B Cell Cancers Clinical Strategy: Use Combination Therapy BCR and TLR Pathways independently drive NF-κB overactivity In preclinical testing, blocking both IRAK4 an

  31. Slide 31: TakeAim Lymphoma: Study Design

    TakeAim Lymphoma: Study Design Examining emavusertib in combination with leading BTK inhibitor Part A1: dose escalation of emavusertib as monotherapy (completed) Part A2: dose escalation of emavusertib in combination with ibrutinib (n=13 data below) Part B: expansion cohorts of emavusertib in combin

  32. Slide 32: TakeAim Lymphoma: Baseline Characteristics and Safety

    TakeAim Lymphoma: Baseline Characteristics and Safety Emavusertib appears well-tolerated with data from six subtypes Emavusertib Emavusertib Total 200 mg BID 300 mg BID Combination therapy Grade 3+ Treatment-Related Adverse (N = 13) Ibrutinib Ibrutinib Ibrutinib Ibrutinib Event 420 mg QD 560 mg QD 4

  33. Slide 33: Responses Seen in Both BTK Naïve and BTK Experienced

    Responses Seen in Both BTK Naïve and BTK Experienced Majority of patients had decreases in tumor burden over time Best Response Change in Tumor Burden Over Time 20 80 SD * Best Percentage Change in Tumor No Prior BTK Treatment Received Prior BTK Treatment 60 0 Percent Change in Tumor Burden from Bur

  34. Slide 34: Responses in Several Subtypes, One Ongoing Nearly a Year

    Responses in Several Subtypes, One Ongoing Nearly a Year Response seen in BTK experienced patient Preliminary Efficacy with Combination Therapy • Preliminary data suggest that MCL combination therapy may overcome MCL ibrutinib resistance in hematological CNS Individual Subject Diagnosis CLL No Prior

  35. Slide 35: Emavusertib in B Cell Cancers

    Emavusertib in B Cell Cancers Emavusertib is the ideal candidate to combine with BTKi to maximize downregulation of NF-κB • Patients are treated with BTKi because downregulating NF-κB activity reduces tumor burden in B Cell Cancers Next Steps: • Two pathways drive NF-κB: Combination Therapy 1) BCR P

  36. Slide 36: VISTA Biology and CI-8993

    r~ CURIS = VISTA Biology and Cl-8993

  37. Slide 37: Anti-cancer Mechanisms of Checkpoint Inhibitors

    Anti-cancer Mechanisms of Checkpoint Inhibitors Role of VISTA may go beyond other checkpoint inhibitors We believe VISTA inhibition has potential for broad application in many tumor types in monotherapy and in combination with existing checkpoint inhibitors Target Checkpoint Inhibitors Approved in M

  38. Slide 38: CI-8993 Preclinical Data

    CI-8993 Preclinical Data Clear anti-cancer activity suggest potential transformation of immune-oncology treatment Monotherapy Combination Therapy Anti-VISTA inhibited tumor growth Anti-VISTA inhibited xenograft growth in B16ova melanoma model1 in checkpoint resistant CT26 model2 Control n=14 100% Da

  39. Slide 39: Incorporated Learnings from CI-8993 Prior Clinical Study

    Incorporated Learnings from CI-8993 Prior Clinical Study Pharmacodynamic activity (cytokine release) observed in initial clinical study CI-8993 is the first anti-VISTA monoclonal antibody (IgG1κ) to be studied in clinical trials • Janssen initiated a Ph1 study in 2016 and enrolled 12 patients1 - Tra

  40. Slide 40: CI-8993 Clinical Plan: Phase 1 Dose Escalation Study

    CI-8993 Clinical Plan: Phase 1 Dose Escalation Study On-going clinical study to determine safety Patient Population • Patients with advanced refractory solid tumors Phase 1 Dose Escalation Study Design (includes mesothelioma, melanoma, NSCLC, TNBC) Treatment Higher Continue dose escalation • Bi-week

  41. Slide 41: CI-8993 Has Demonstrated Favorable Safety Profile

    CI-8993 Has Demonstrated Favorable Safety Profile Successfully managed expected CRS at all levels dosed to date All Grades 0.15 mg/kg 0.3 mg/kg Grade 3+ 0.15 mg/kg 0.3 mg/kg Treatment-Related Adverse Events (N = 7) (N = 5) Treatment-Related Adverse Events (N = 7) (N = 5) Occurring in 2+ Patients n (

  42. Slide 42: CI-8993 Has Demonstrated Favorable PK Profile

    CI-8993 Has Demonstrated Favorable PK Profile CI-8993 mean plasma concentration vs. time profile following IV administration at full dose Plasma Concentration Cmax Levels 1,000,000 1,000,000 Mean 0.15 mpk DAY 1 (ng/mL) Concentration(ng/mL) Mean 0.15 mpk DAY 29 78.4-fold Mean 0.3 mpk DAY 1 100,000 10

  43. Slide 43: Pharmacodynamic Effects of CI-8993 in Patients

    Pharmacodynamic Effects of CI-8993 in Patients CI-8993 affects multiple anticancer mechanisms supporting VISTA potential Decreased recruitment of MDSCs NK Cell Activation 1 2 Decreased CXCR2 on granulocytes Decreased CD16 on NK cells CI-8993 reduces MDSCs Cohort 1 Cohort 2 Cohort 1 Cohort 2 CI-8993

  44. Slide 44: Pharmacodynamic Effects of CI-8993 in Patients

    Pharmacodynamic Effects of CI-8993 in Patients CI-8993 affects multiple anticancer mechanisms supporting VISTA potential Enhanced Antigen Presentation Release of T-Cell Activating Factors 4 5 Increased HLA-DR on Monocytes Increased Secretion of IP10 CI-8993 enhances antigen Cohort 1 Cohort 2 Cohort

  45. Slide 45: CI-8993 Cleared Initial Safety Hurdle

    CI-8993 Cleared Initial Safety Hurdle First-in-class CI-8993 has potential for broad applicability in immune checkpoint therapy • Encouraging initial safety data appears to demonstrate effectiveness of procedures implemented to manage expected CRS Next Steps in Dose Escalation • Continue dose-escala

  46. Slide 46: Corporate Overview

    Corporate Overview Summary Curis seeks to develop novel, first-in-class, cancer therapeutics Investment that we believe have significant potential in areas of unmet patient need Thesis Cash and investments of approximately $120.7M as of March 31, 2022; cash runway into 2024 Emavusertib: first-in-cla

  47. Slide 47: Committed, Experienced Leadership Team

    Curis Committed, Experienced Leadership Team Rachel Blasbalg James Dentzer Christine Guertin Robert Martell Head, Human Resources President & CEO Head, Regulatory Head, R&D Mark Noel Reinhard von Roemeling Raul Soikes Nancy Soohoo William Steinkrauss Head, Intellectual Property Head, Clinical Develo

  48. Slide 48: End of Corporate Presentation

    End of Corporate Presentation NASDAQ: CRIS

  49. Slide 49: Appendix

    APPENDIX

  50. Slide 50: Dose Response in Single Patient at Multiple Dose Levels

    Dose Response in Single Patient at Multiple Dose Levels Patient in dose escalation phase of TakeAim Lymphoma study Dose Response Observed in WM Patient (50mg - 300mg BID) Clear Single Agent Anti-Cancer Activity • Tumor burden decreased with each increase in dose (objective response observed at RP2D)

Curis — Investor Presentation (June 2022) on 6ix